Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 8/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051030 | 0.94 | ALDH1A1 (0.50) | CTSDALDH1A1NPSR1ENPEPL3MBTL1 | |
| SCHEMBL30051556 | 0.94 | ALDH1A1 (0.53) | CTSDALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL29750817 | 0.90 | MME (0.49) | CTSDALDH1A1ENPEP | |
| SCHEMBL29380611 | 0.89 | NPSR1 (0.47) | CTSDALDH1A1NPSR1 | |
| SCHEMBL30052811 | 0.87 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL935682 | 0.87 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL8641181 | 0.87 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL935683 | 0.87 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL18613512 | 0.86 | MME (0.54) | ALDH1A1ENPEPL3MBTL1 | |
| SCHEMBL18613513 | 0.86 | MME (0.54) | ALDH1A1ENPEPL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSD 503/4885ALDH1A1 3596/4885NPSR1 2720/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSD 213/4885ALDH1A1 4110/4885NPSR1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.